Explaining cancer type specific mutations with transcriptomic and epigenomic features in normal tissues

• Published in: Scientific reports Vol. 8; no. 1; pp. 11456 - 12
• Main Authors: Tiong, Khong-Loon, Yeang, Chen-Hsiang
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 30.07.2018; Nature Publishing Group
• Subjects: 631/114/2403; 631/67/69; Cancer; Cell adhesion; Cell proliferation; Chromatin; DNA repair; Gene expression; Gene frequency; Gene set enrichment analysis; Genomes; Humanities and Social Sciences; multidisciplinary; Mutation; Protein interaction; Science; Science (multidisciplinary); Tumors
• DOI: 10.1038/s41598-018-29861-1
• ISSN: 2045-2322

Most cancer driver genes are involved in generic cellular processes such as DNA repair, cell proliferation and cell adhesion, yet their mutations are often confined to specific cancer types. To resolve this paradox, we explained mutation frequencies of selected genes across tumor types with four features in the corresponding normal tissues from cancer-free subjects: mRNA expression and chromatin accessibility of mutated genes, mRNA expressions of their neighbors in curated pathways and the protein-protein interaction network. Encouragingly, these transcriptomic/epigenomic features in normal tissues were closely associated with mutational/functional characteristics in tumors. First, chromatin accessibility was a necessary but not sufficient condition for frequent mutations. Second, variations of mutation frequencies in selected genes across tissue types were significantly associated with all four features. Third, the genes possessing significant associations between mutation frequency variations and pathway gene expression were enriched with documented cancer genes. We further proposed a novel bivariate gene set enrichment analysis and confirmed that the pathway gene expression was the dominant factor in cancer gene enrichment. These findings shed lights on the functional roles of genes in normal tissues in shaping the mutational landscape during tumor genome evolution.